Andrew Tsai
Stock Analyst at Jefferies
(0.20)
# 4,102
Out of 4,825 analysts
17
Total ratings
20%
Success rate
-33.38%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Tsai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AXSM Axsome Therapeutics | Initiates: Buy | $200 | $112.47 | +77.83% | 1 | Apr 7, 2025 | |
| BEKE KE Holdings | Maintains: Overweight | $19 → $27 | $20.53 | +31.51% | 2 | Mar 19, 2025 | |
| RCKT Rocket Pharmaceuticals | Initiates: Buy | $29 | $7.88 | +268.02% | 1 | Dec 18, 2024 | |
| SRPT Sarepta Therapeutics | Initiates: Buy | $165 | $62.78 | +162.82% | 1 | Oct 21, 2024 | |
| RLMD Relmada Therapeutics | Upgrades: Buy | $3.5 → $13 | $0.35 | +3,667.02% | 2 | Sep 17, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | $35 | $11.47 | +205.14% | 1 | Jul 2, 2024 | |
| ANRO Alto Neuroscience | Initiates: Buy | $33 | $2.43 | +1,258.02% | 1 | Feb 27, 2024 | |
| VTGN Vistagen Therapeutics | Upgrades: Buy | $0.2 → $15 | $2.36 | +535.59% | 2 | Dec 7, 2023 | |
| LXRX Lexicon Pharmaceuticals | Initiates: Hold | $3 | $0.72 | +314.08% | 1 | Mar 7, 2023 | |
| ATHA Athira Pharma | Downgrades: Hold | $32 → $3 | $0.29 | +952.63% | 2 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $2.56 | +681.25% | 1 | Feb 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $1.47 | +1,736.73% | 1 | Sep 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $16 → $23 | $38.21 | -39.81% | 1 | Jun 1, 2020 | |
Axsome Therapeutics
Apr 7, 2025
Initiates: Buy
Price Target: $200
Current: $112.47
Upside: +77.83%
KE Holdings
Mar 19, 2025
Maintains: Overweight
Price Target: $19 → $27
Current: $20.53
Upside: +31.51%
Rocket Pharmaceuticals
Dec 18, 2024
Initiates: Buy
Price Target: $29
Current: $7.88
Upside: +268.02%
Sarepta Therapeutics
Oct 21, 2024
Initiates: Buy
Price Target: $165
Current: $62.78
Upside: +162.82%
Relmada Therapeutics
Sep 17, 2024
Upgrades: Buy
Price Target: $3.5 → $13
Current: $0.35
Upside: +3,667.02%
Rapport Therapeutics
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $11.47
Upside: +205.14%
Alto Neuroscience
Feb 27, 2024
Initiates: Buy
Price Target: $33
Current: $2.43
Upside: +1,258.02%
Vistagen Therapeutics
Dec 7, 2023
Upgrades: Buy
Price Target: $0.2 → $15
Current: $2.36
Upside: +535.59%
Lexicon Pharmaceuticals
Mar 7, 2023
Initiates: Hold
Price Target: $3
Current: $0.72
Upside: +314.08%
Athira Pharma
Jun 23, 2022
Downgrades: Hold
Price Target: $32 → $3
Current: $0.29
Upside: +952.63%
Feb 1, 2022
Initiates: Buy
Price Target: $20
Current: $2.56
Upside: +681.25%
Sep 1, 2021
Initiates: Buy
Price Target: $27
Current: $1.47
Upside: +1,736.73%
Jun 1, 2020
Assumes: Buy
Price Target: $16 → $23
Current: $38.21
Upside: -39.81%